Journal of the Royal Statistical Society: Series C (Applied Statistics)

Table of Contents

Volume 68 Issue 2 (February 2019)


Issue Information

Issue Information

  • Author:
  • Pub Online: Jan 11, 2019
  • DOI: 10.1111/rssc.12301 (p 265-266)


Preface to the themed issue on ‘Early phase clinical trial design methodology’

  • Author: Nolan A. Wages, Ying Yuan
  • Pub Online: Jan 11, 2019
  • DOI: 10.1111/rssc.12329 (p 267-269)

Semiparametric dose finding methods: special cases

  • Author: M. Clertant, J. O’Quigley
  • Pub Online: Aug 17, 2018
  • DOI: 10.1111/rssc.12308 (p 271-288)

gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points

  • Author: Rongji Mu, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, Jun Yin
  • Pub Online: Feb 16, 2018
  • DOI: 10.1111/rssc.12263 (p 289-308)

A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data

  • Author: Graham M. Wheeler, Michael J. Sweeting, Adrian P. Mander
  • Pub Online: Nov 22, 2018
  • DOI: 10.1111/rssc.12323 (p 309-329)

Phase I–II trial design for biologic agents using conditional auto‐regressive models for toxicity and efficacy

  • Author: Daniel G. Muenz, Jeremy M. G. Taylor, Thomas M. Braun
  • Pub Online: Oct 07, 2018
  • DOI: 10.1111/rssc.12314 (p 331-345)

An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity

  • Author: Pavel Mozgunov, Thomas Jaki
  • Pub Online: Jun 15, 2018
  • DOI: 10.1111/rssc.12293 (p 347-367)

Joint modelling of a binary and a continuous outcome measured at two cycles to determine the optimal dose

  • Author: Monia Ezzalfani, Tomasz Burzykowski, Xavier Paoletti
  • Pub Online: Aug 17, 2018
  • DOI: 10.1111/rssc.12305 (p 369-384)

AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual‐agent dose finding trials

  • Author: Jiaying Lyu, Yuan Ji, Naiqing Zhao, Daniel V. T. Catenacci
  • Pub Online: Jun 13, 2018
  • DOI: 10.1111/rssc.12291 (p 385-410)

A utility‐based Bayesian phase I–II design for immunotherapy trials with progression‐free survival end point

  • Author: Beibei Guo, Yeonhee Park, Suyu Liu
  • Pub Online: May 18, 2018
  • DOI: 10.1111/rssc.12288 (p 411-425)

A dose finding design for seizure reduction in neonates

  • Author: Moreno Ursino, Ying Yuan, Corinne Alberti, Emmanuelle Comets, Geraldine Favrais, Tim Friede, Frederike Lentz, Nigel Stallard, Sarah Zohar
  • Pub Online: May 18, 2018
  • DOI: 10.1111/rssc.12289 (p 427-444)

Dose individualization and variable selection by using the Bayesian lasso in early phase dose finding trials

  • Author: Yasuyuki Kakurai, Shuhei Kaneko, Chikuma Hamada, Akihiro Hirakawa
  • Pub Online: Nov 22, 2018
  • DOI: 10.1111/rssc.12326 (p 445-460)

Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times

  • Author: Juhee Lee, Peter F. Thall, Katy Rezvani
  • Pub Online: Mar 15, 2018
  • DOI: 10.1111/rssc.12271 (p 461-474)

Treatment and dose prioritization in early phase platform trials of targeted cancer therapies

  • Author: Yimei Li, Ming Wang, Ying Kuen Cheung
  • Pub Online: Dec 02, 2018
  • DOI: 10.1111/rssc.12324 (p 475-491)

Related Topics

Related Publications

Related Content

Site Footer


This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.